These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8254775)

  • 1. Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences.
    Smith AD; Resnick DA; Zhang A; Geisler SC; Arnold E; Arnold GF
    J Virol; 1994 Jan; 68(1):575-9. PubMed ID: 8254775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Libraries of human rhinovirus-based HIV vaccines generated using random systematic mutagenesis.
    Resnick DA; Smith AD; Zhang A; Geisler SC; Arnold E; Arnold GF
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S47-52. PubMed ID: 7865333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1.
    Resnick DA; Smith AD; Gesiler SC; Zhang A; Arnold E; Arnold GF
    J Virol; 1995 Apr; 69(4):2406-11. PubMed ID: 7884887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A disulfide-bound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1.
    Zhang A; Geisler SC; Smith AD; Resnick DA; Li ML; Wang CY; Looney DJ; Wong-Staal F; Arnold E; Arnold GF
    Biol Chem; 1999 Mar; 380(3):365-74. PubMed ID: 10223339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1.
    Smith AD; Geisler SC; Chen AA; Resnick DA; Roy BM; Lewi PJ; Arnold E; Arnold GF
    J Virol; 1998 Jan; 72(1):651-9. PubMed ID: 9420270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza, and human immunodeficiency viruses.
    Arnold GF; Resnick DA; Li Y; Zhang A; Smith AD; Geisler SC; Jacobo-Molina A; Lee W; Webster RG; Arnold E
    Virology; 1994 Feb; 198(2):703-8. PubMed ID: 7507283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
    Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
    J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
    Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
    J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization.
    Robert-Guroff M; Louie A; Myagkikh M; Michaels F; Kieny MP; White-Scharf ME; Potts B; Grogg D; Reitz MS
    J Virol; 1994 Jun; 68(6):3459-66. PubMed ID: 7514675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.
    Inouye P; Cherry E; Hsu M; Zolla-Pazner S; Wainberg MA
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):735-40. PubMed ID: 9643373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.
    Schreiber M; Petersen H; Wachsmuth C; Müller H; Hufert FT; Schmitz H
    J Virol; 1994 Jun; 68(6):3908-16. PubMed ID: 8189527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein engineering to create biologically active peptides: recombinant human rhinoviruses that display peptide sequences.
    Smith AD; Arnold E; Arnold GF
    Behring Inst Mitt; 1997 Feb; (98):229-39. PubMed ID: 9382744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes.
    Arnold GF; Resnick DA; Smith AD; Geisler SC; Holmes AK; Arnold E
    Intervirology; 1996; 39(1-2):72-8. PubMed ID: 8957672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. V3 loop core region serotyping of HIV-1 infected patients using the FHV epitope presenting system.
    Schiappacassi M; Buratti E; D'Agaro P; Ciani L; Scodeller ES; Tisminetzky SG; Baralle FE
    J Virol Methods; 1997 Jan; 63(1-2):121-7. PubMed ID: 9015282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
    J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
    Schønning K; Jansson B; Olofsson S; Hansen JE
    J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.